VSIR and non-small cell lung carcinoma: Due to the absence of existing targeted therapies for mTORC2 and the modest success of immunotherapy in NSCLC [38–40], we sought to test if anti-VISTA immunotherapy can boost antitumor T cell activity and restrict LUSC growth.